| Patient | Judy Garland |
|---|---|
| Date of birth | 1993-06-10 |
| Identifiers | MRN HR-ML005-SYN; SSN (made up) 000-05-6127 |
| Document date | 2026-11-01 |
| Author | Margaret Ellsworth-Diaz, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing primary care for long-term prescribed sleeping pills and stimulants that began in adolescence: a nonjudgmental assessment, a prescription drug monitoring program review, sleep, mood, anxiety and safety, nutrition, and contraception three months after childbirth. Concerns: She wants to stop needing pills to sleep and to work, without being made to feel she is to blame for them; She is afraid of being unable to sleep or perform during the change; She worries about her weight if she stops the stimulant. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Secobarbital 100 mg oral capsule, two capsules (200 mg) at bedtime; prescribed elsewhere for years; continued by this clinic at the verified dose, seven days at a time, until a supervised withdrawal is planned with addiction medicine | Two capsules at bedtime; no extra doses | Oral route | 2026-06-22 to 2026-07-06 | completed | S |
| Dextroamphetamine 10 mg oral tablet, one tablet each morning; no extra doses; prescribed elsewhere for weight and energy | One tablet each morning | Oral route | 2026-06-22 to 2026-07-20 | completed | S |
| Dextroamphetamine 5 mg oral tablet, one tablet each morning for two weeks, then stop | One tablet each morning for two weeks, then stop | Oral route | 2026-07-20 to 2026-08-03 | completed | S |
| Sertraline 25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-06-22 to 2026-06-29 | completed | S |
| Sertraline 50 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-06-29 | active | S |
| Phenobarbital 32.4 mg oral tablet, one tablet three times daily (97.2 mg a day), started in hospital in place of secobarbital | One tablet three times daily | Oral route | 2026-07-06 to 2026-07-20 | completed | S |
| Phenobarbital 16.2 mg oral tablet on a written taper schedule in two or three divided doses: 81 mg a day from the four-week visit, lowered by 8.1 to 16.2 mg about every two weeks and paused when needed; dispensed two weeks at a time | Per the written taper schedule, in two or three divided doses | Oral route | 2026-07-20 | active | S |
| Medroxyprogesterone acetate 150 mg/mL injection, 150 mg into the muscle every 13 weeks | 150 mg intramuscularly every 13 weeks | Intramuscular route | 2026-06-22 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for throat pain, no more than 3,000 mg a day, for up to five days | Two tablets every 6 hours as needed, up to 3,000 mg a day | Oral route | 2026-08-17 to 2026-08-22 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Twelve-lead electrocardiogram before continuing a stimulant | 2026-06-22 to 2026-06-22 | completed | S |
| Medically managed barbiturate withdrawal: four-day hospital admission to the addiction medicine service to change secobarbital to phenobarbital, with withdrawal scoring, seizure precautions and dose stabilization | 2026-07-06 to 2026-07-09 | completed | S |
| Advance care planning conversation, about 17 minutes | 2026-09-28 to 2026-09-28 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-06-22 | Tdap vaccine | completed | S |
| 2026-09-28 | Influenza vaccine, inactivated, this season | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| by 1939 | Stimulant pills for appetite and energy and barbiturate sleeping pills given to her as a teenage studio performer, with dependence on prescribed medicines since | D (CLM-0003, CLM-0005) |
| 1949 | Hospital and sanitarium stays in her twenties, publicly described as treatment for exhaustion | D (CLM-0007) |
| 1950 | Suicide attempts reported publicly, including one in 1950; recorded without detail | D (CLM-0006) |
| March 1955 | Birth of her third child three months before the index visit | D (CLM-0010) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| She wants to stop needing pills to sleep and to work, without being made to feel she is to blame for them | active | S |
| She is afraid of being unable to sleep or perform during the change | active | S |
| She worries about her weight if she stops the stimulant | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 12.9 on 2026-10-26; MCV [Entitic mean volume] in Red Blood Cells by Automated count 87 on 2026-10-26; Platelets [#/volume] in Blood by Automated count 268 on 2026-10-26; Ferritin [Mass/volume] in Serum or Plasma 41 on 2026-10-26; Sodium [Moles/volume] in Serum or Plasma 140 on 2026-10-26; Potassium [Moles/volume] in Serum or Plasma 4.2 on 2026-10-26; Creatinine [Mass/volume] in Serum or Plasma 0.68 on 2026-10-26; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 118 on 2026-10-26; Glucose [Mass/volume] in Serum or Plasma 82 on 2026-06-22; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 23 on 2026-10-26; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 20 on 2026-10-26; Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma 48 on 2026-10-26; Thyrotropin [Units/volume] in Serum or Plasma 1.9 on 2026-06-22; Total score [DAST-10] 6 on 2026-06-22; Total score [AUDIT-C] 2 on 2026-06-22; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 5 on 2026-10-26; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 5 on 2026-10-26 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Sedative, hypnotic, or anxiolytic use disorder (barbiturate), moderate, with physiological dependence; began with sleeping pills given in adolescence; synthetic modern episode linked to her documented lifelong dependence on prescribed sleeping pills | active | confirmed | F13.20 | S — Synthetic modern coding. Tolerance and withdrawal are not counted toward the diagnosis for a medicine taken under medical supervision; five other criteria are met. Person-first language; not a claim about her real diagnosis. |
| Stimulant use disorder (prescribed amphetamine), mild; began with stimulants given in adolescence for weight and energy; synthetic modern episode linked to her documented pep pills | active | confirmed | F15.10 | S — Synthetic modern coding; DSM-5-TR mild stimulant use disorder maps to F15.10. Tolerance and withdrawal are not counted for a supervised prescription. |
| Chronic insomnia disorder, long-standing, with sleep tied to sleeping pills since adolescence | active | confirmed | G47.00 | S — Synthetic modern diagnosis anchored to the documented sleeping pills. |
| Contraception three months after childbirth while starting an enzyme-inducing drug: injectable progestin chosen because barbiturates, including any used for the withdrawal, weaken contraceptive pills, patches, rings and implants | active | confirmed | Z30.013 | S — Synthetic contraception need; the birth is documented. |
| Major depressive disorder, single episode, moderate, with anxious distress; Mood Disorder Questionnaire negative and no history of mania or hypomania | active | confirmed | F32.1 | S — Synthetic modern diagnosis; not a claim about her real mood. The roster's bipolar disorder lead is not supported by the sources read and is not used. |
| Acute laryngitis, probably viral, during rehearsals, treated with voice rest and supportive care; resolved | resolved | confirmed | J04.0 | S — Synthetic acute illness; not a historical claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-22 | Hemoglobin [Mass/volume] in Blood | 12.3 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-06-22 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 86 | fL | 80-100 fL | Normal | S |
| 2026-06-22 | Platelets [#/volume] in Blood by Automated count | 284 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-06-22 | Ferritin [Mass/volume] in Serum or Plasma | 24 | ng/mL | 15-150 ng/mL | Normal | S |
| 2026-06-22 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-06-22 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-06-22 | Creatinine [Mass/volume] in Serum or Plasma | 0.66 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-06-22 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 119 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-06-22 | Glucose [Mass/volume] in Serum or Plasma | 82 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-06-22 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 10-35 U/L | Normal | S |
| 2026-06-22 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 | U/L | 7-35 U/L | Normal | S |
| 2026-06-22 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 5-40 U/L | Normal | S |
| 2026-06-22 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 2026-06-22 | Total score [DAST-10] | 6 | {score} | S | ||
| 2026-06-22 | Total score [AUDIT-C] | 2 | {score} | S | ||
| 2026-06-22 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 14 | {score} | S | ||
| 2026-06-22 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 13 | {score} | S | ||
| 2026-07-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 12 | {score} | S | ||
| 2026-07-20 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 11 | {score} | S | ||
| 2026-08-31 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 9 | {score} | S | ||
| 2026-08-31 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | {score} | S | ||
| 2026-09-28 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-10-26 | Hemoglobin [Mass/volume] in Blood | 12.9 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-10-26 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 87 | fL | 80-100 fL | Normal | S |
| 2026-10-26 | Platelets [#/volume] in Blood by Automated count | 268 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-10-26 | Ferritin [Mass/volume] in Serum or Plasma | 41 | ng/mL | 15-150 ng/mL | Normal | S |
| 2026-10-26 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-10-26 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 0.68 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 118 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-26 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 23 | U/L | 10-35 U/L | Normal | S |
| 2026-10-26 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | 7-35 U/L | Normal | S |
| 2026-10-26 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 48 | U/L | 5-40 U/L | High | S |
| 2026-10-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-10-26 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 5 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-22 | Body height | 151 | cm | S |
| 2026-06-22 | Body weight | 46.5 | kg | S |
| 2026-06-22 | Body mass index (BMI) [Ratio] | 20.4 | kg/m2 | S |
| 2026-06-22 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-06-22 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 2026-06-22 | Heart rate | 98 | /min | S |
| 2026-06-22 | Respiratory rate | 16 | /min | S |
| 2026-06-22 | Body temperature | 36.8 | Cel | S |
| 2026-06-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-06-29 | Body height | 151 | cm | S |
| 2026-06-29 | Body weight | 46.8 | kg | S |
| 2026-06-29 | Body mass index (BMI) [Ratio] | 20.5 | kg/m2 | S |
| 2026-06-29 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-06-29 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-06-29 | Heart rate | 92 | /min | S |
| 2026-06-29 | Respiratory rate | 16 | /min | S |
| 2026-06-29 | Body temperature | 36.7 | Cel | S |
| 2026-06-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-07-20 | Body height | 151 | cm | S |
| 2026-07-20 | Body weight | 47.6 | kg | S |
| 2026-07-20 | Body mass index (BMI) [Ratio] | 20.9 | kg/m2 | S |
| 2026-07-20 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-07-20 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-07-20 | Heart rate | 82 | /min | S |
| 2026-07-20 | Respiratory rate | 14 | /min | S |
| 2026-07-20 | Body temperature | 36.6 | Cel | S |
| 2026-07-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-08-31 | Body height | 151 | cm | S |
| 2026-08-31 | Body weight | 48.9 | kg | S |
| 2026-08-31 | Body mass index (BMI) [Ratio] | 21.4 | kg/m2 | S |
| 2026-08-31 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-08-31 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-08-31 | Heart rate | 72 | /min | S |
| 2026-08-31 | Respiratory rate | 14 | /min | S |
| 2026-08-31 | Body temperature | 36.7 | Cel | S |
| 2026-08-31 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-10-26 | Body height | 151 | cm | S |
| 2026-10-26 | Body weight | 50 | kg | S |
| 2026-10-26 | Body mass index (BMI) [Ratio] | 21.9 | kg/m2 | S |
| 2026-10-26 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-10-26 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-10-26 | Heart rate | 68 | /min | S |
| 2026-10-26 | Respiratory rate | 14 | /min | S |
| 2026-10-26 | Body temperature | 36.6 | Cel | S |
| 2026-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-09-28 | Body height | 151 | cm | S |
| 2026-09-28 | Body weight | 49.4 | kg | S |
| 2026-09-28 | Body mass index (BMI) [Ratio] | 21.7 | kg/m2 | S |
| 2026-09-28 | Systolic blood pressure | 110 | mm[Hg] | S |
| 2026-09-28 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-09-28 | Heart rate | 70 | /min | S |
| 2026-09-28 | Respiratory rate | 14 | /min | S |
| 2026-09-28 | Body temperature | 36.6 | Cel | S |
| 2026-09-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-08-17 | Body height | 151 | cm | S |
| 2026-08-17 | Body weight | 48.4 | kg | S |
| 2026-08-17 | Body mass index (BMI) [Ratio] | 21.2 | kg/m2 | S |
| 2026-08-17 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-08-17 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-08-17 | Heart rate | 84 | /min | S |
| 2026-08-17 | Respiratory rate | 16 | /min | S |
| 2026-08-17 | Body temperature | 37.6 | Cel | S |
| 2026-08-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-06-22 | Establishing primary care for long-term prescribed sleeping pills and stimulants that began in adolescence: a nonjudgmental assessment, a prescription drug monitoring program review, sleep, mood, anxiety and safety, nutrition, and contraception three months after childbirth | finished | S |
| 2026-06-29 | One-week review with the addiction medicine consultation: planning a supervised barbiturate withdrawal | finished | S |
| 2026-07-20 | Four-week review eleven days after a supervised hospital change from secobarbital to phenobarbital: starting the outpatient taper and the stimulant taper | finished | S |
| 2026-08-31 | Ten-week review: phenobarbital taper, life after stopping the stimulant, sleep, mood, weight and work | finished | S |
| 2026-10-26 | Four-month review: phenobarbital taper, sleep, mood, laboratory checks and the plan to finish | finished | S |
| 2026-09-28 | Periodic adult preventive visit | finished | S |
| 2026-08-17 | Same-day sick visit for acute laryngitis | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Safe prescribing of controlled drugs: one prescriber and one pharmacy, a prescription drug monitoring program check before every controlled-substance prescription, a written shared treatment agreement, urine drug testing explained as part of care, seven-day supplies at first, a locked box, and take-back of unused capsules | completed | GL-BZD-TAPER-2025, GL-CDC-PDMP | S |
| Addiction medicine consultation to confirm the diagnoses, plan a safe barbiturate withdrawal and taper, and advise on stopping the stimulant | completed | GL-BZD-TAPER-2025, GL-ASAM-AWM-2020, GL-ASAM-STIM-2024 | S |
| Supervised barbiturate withdrawal: a short hospital admission to change secobarbital to phenobarbital with withdrawal scoring and seizure precautions, then a slow outpatient phenobarbital taper of no more than about 20% every two weeks, slower toward the end, paused for withdrawal symptoms, illness or a major performance, never stopped abruptly; no benzodiazepine or Z-drug in its place; no alcohol | completed | GL-BZD-TAPER-2025, GL-ASAM-AWM-2020 | S |
| Stimulant: dextroamphetamine held at one fixed morning dose until phenobarbital is stable, then 5 mg for two weeks and stopped, with mood, sleep and appetite checks; no other stimulant | completed | GL-ASAM-STIM-2024 | S |
| Insomnia: cognitive behavioral therapy for insomnia as first-line treatment, adapted to late performances (a fixed wake time, a wind-down routine after shows, sleep restriction only after the taper is stable), with a sleep diary; no new hypnotic | completed | GL-ACP-INSOMNIA-2016, GL-AASM-INSOMNIA-2017 | S |
| Depression and anxiety: PHQ-9 and GAD-7 at each visit, sertraline, weekly psychotherapy, the Mood Disorder Questionnaire before the antidepressant, a structured safety assessment with a written safety plan, means safety and the 988 Suicide & Crisis Lifeline, and safety review at every visit | completed | GL-CMID-2026, GL-USPSTF-DEP-2023, GL-SUICIDE-2024 | S |
| Nutrition and weight without stigma: regular meals and snacks around rehearsals, a dietitian visit, no weight-loss target and no dieting drugs, and screening for disordered eating | completed | GL-ASAM-STIM-2024 | S |
| Contraception that barbiturates do not weaken: medroxyprogesterone injection every 13 weeks, after a negative pregnancy test, with an intrauterine device as an alternative | completed | GL-CDC-MEC-2024 | S |
| Naloxone not prescribed: she takes no opioid, has no opioid prescription in the monitoring program, her urine test shows no opioids or fentanyl, and all her pills come from a pharmacy; naloxone does not reverse a barbiturate overdose. To be offered at once if an opioid is ever prescribed or any pill comes from outside a pharmacy | completed | GL-ASAM-STIM-2024, GL-CDC-PDMP | S |
| Work: taper steps scheduled away from major performances, a written plan for late nights and travel, and letters she controls | completed | GL-BZD-TAPER-2025 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Change from secobarbital to phenobarbital under supervision without a withdrawal seizure or delirium | 2026-07-20 | completed | Four-day supervised admission; no seizure, delirium or severe withdrawal | S |
| Lower the phenobarbital dose slowly, at no more than about 20% every two weeks, toward stopping | 2026-10-26 | active | 97.2 mg a day at discharge to 32.4 mg a day at four months; two pauses when needed; taper continuing | S |
| Stop dextroamphetamine with a short taper and no return to it | 2026-08-31 | completed | Stopped after a two-week taper; tiredness for about two weeks, then better | S |
| Sleep six hours or more on most nights using CBT for insomnia | 2026-10-26 | active | About six hours on most nights; rebound wakefulness after each dose step settles within a week | S |
| PHQ-9 below 5 by six months | 2026-10-26 | active | PHQ-9 14 to 5 at four months; response | S |
| Regular meals and weight she is comfortable with, without dieting drugs | 2026-10-26 | completed | Three meals on most days; weight up 3.5 kg to a BMI of 21.9; she says she feels stronger | S |
Structured synthetic safety assessment on 2026-06-22: current ideation absent, intent absent, plan absent. Outpatient care with close follow-up. Risk factors reviewed without detail: past suicide attempts reported in earlier years, a sedative use disorder, depression, the months after childbirth, and the low mood that can follow stopping a stimulant. Barbiturates are dangerous in overdose, so means safety is part of the plan: she agreed to take the unused capsules from earlier prescriptions to a pharmacy take-back at the next visit, to keep the current supply in a locked box, and to receive no more than seven days at a time. No alcohol with the barbiturate. A written safety plan was made with her, and the 988 Suicide & Crisis Lifeline (call or text 988) was saved in her phone. Safety is reviewed at every visit [S]